Boehringer Ingelheim and Gubra send obesity drug candidate to clinical trial
Years of collaboration among Gubra and Boehringer Ingelheim have now entered a new phase after the partnership's first potential drug has entered clinical trials on human subjects.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL FRANK CHRISTENSEN
The first possible medicament from Danish biotechnology and contract research organization Gubra's partnership with Germany's Boehringer Ingelheim has now entered its first clinical trial phase, the latter informs in a press statement.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
